ADMA News & Events

The major averages closed lower following yesterday's gains. The bounce yesterday was driven by headlines suggesting a de-escalation with Iran, but that narrative is already fraying. Oil has turned higher again, climbing back above $90 for the WTI benchmark as optimism fades and the reality of disrupted supply through the Strait of Hormuz reasserts itself.Meanwhile, The Wall Street Journal reported that the Pentagon intends to deploy 3,000 Airborne U.S. soldiers to the Middle East. A written order to deploy the unit is expected later Wednesday, officials told The Journal.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Estee Lauderconfirmed it is inwith Puig BrandsSmithfield Foodsreportedand provided FY26 revenue guidanceNetgearsurged following reports that the FCC hasSumitomo Mitsuiis considering a potential takeover of Jefferies,Ares Managementsaid it isin the Ares Strategic Income fund2. WALL STREET CALLS:UBSJFrogto Buy after 30% AI-driven selloffCoreWeaveat Buy at BofACitiRalph Laurento Buy on post-selloff opportunityJPMorganXencoron a lack of "needle-moving" catalystsUltragenyxto Neutral from Buy at Goldman Sachs3. AROUND THE WEB:OpenAI is set to raise about $10B from venture investors, Bloomberg reportsCulper Research is short Adma Biologics, saying the company's reported growth is "a fiction"Microsoftto rent data center project in Texas dropped by Oracle, Bloomberg saysSouth Korean AI startup Upstage is in talks to acquire 10K AMDMI355 chips, in a bid to "diversify to other chips" as "we have a lot of Nvidiachips," Bloomberg reportsPalantirhas been awarded a three-month contract by the UK's Financial Conduct Authority to analyze sensitive internal data in an effort to combat financial crime, sparking concerns about the U.S. firm's expanding role in the British state, The Guardian says4. MOVERS:Applied Optoelectronicsincreased after receiving afrom a hyperscale customerSM Energygained after Truistcoverage of the stock with a Buy ratingHesaislipped afterand providing guidance for Q1Ocugenfell afterfrom its ArMaDa trial of OCU410Trade Deskwas lower afterthat Omnicomis auditing Trade Desk's fees5. EARNINGS/GUIDANCE:Core & Mainand provided guidance for Q1 and FY26, with CEO Mark Witkowski commenting, "Fiscal 2025 marked our 16th consecutive year of sales growth"Concentrix, with EPS missing consensusAchieve Life Sciences, with EPS in-line with consensusCore LaboratoriesprovidedNeurogene, with EPS higher year-over-yearINDEXES:The Dow fell 84.41, or 0.18%, to 46,124.06, the Nasdaq lost 184.86, or 0.84%, to 21,761.90, and the S&P 500 declined 24.63, or 0.37%, to 6,556.37.

ADMA Biologics (ADMA) announced a capital return initiative target of approximately $200M during 2026, including the execution of a $125M accelerated share repurchase agreement with JPMorgan Chase Bank (JPM), National Association. Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of $125M and will initially receive approximately 6.4M shares of its common stock on or about March 3, representing approximately 80% of the shares expected to be repurchased under the ASR, based on the closing price of ADMA's common stock of $15.57 per share on February 27. The total number of shares ultimately repurchased will be based on the average of the daily volume-weighted average price of the Company's common stock during the term of the ASR, less an agreed discount, and is expected to be completed within the next five months. At final settlement, the Company may receive additional shares or, under certain limited circumstances, may be required to deliver shares or make a cash payment, pursuant to the terms of the agreement. The ASR agreement was executed pursuant to the Company's existing share repurchase program, under which the Company has up to $500M authorized for repurchases. The Company intends to be opportunistic in deploying these repurchases, which may include repurchases under Rule 10b5-1 trading plans or in other open market transactions in accordance with SEC Rule 10b-18 over the course of 2026, subject to market conditions and other factors.

"We are pleased with our performance in 2025 and the strong exit momentum we are carrying into 2026," said Adam Grossman, President and Chief Executive Officer of ADMA. "Record ASCENIV demand, anticipated payer coverage expansion, and increasing confidence in long-term plasma supply availability are expected to reinforce the durability of our growth engine and provide clear visibility into accelerating revenue generation as we enter 2026."